For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Zymeworks BC Inc (NASDAQ: ZYME) was $12.63 for the day, up 3.19% from the previous closing price of $12.24. In other words, the price has increased by $3.19 from its previous closing price. On the day, 0.53 million shares were traded. ZYME stock price reached its highest trading level at $12.65 during the session, while it also had its lowest trading level at $12.11.
Ratios:
Our analysis of ZYME’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.71 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On December 16, 2024, JP Morgan Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $18.
Leerink Partners Upgraded its Market Perform to Outperform on November 07, 2024, whereas the target price for the stock was revised from $10 to $25.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 15 ’25 when EcoR1 Capital, LLC bought 49,502 shares for $11.43 per share. The transaction valued at 565,847 led to the insider holds 17,877,989 shares of the business.
EcoR1 Capital, LLC bought 5,919 shares of ZYME for $69,738 on May 19 ’25. The Director now owns 17,883,908 shares after completing the transaction at $11.78 per share. On Apr 16 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 73,953 shares for $11.16 each. As a result, the insider paid 825,589 and bolstered with 17,773,727 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 880102656 and an Enterprise Value of 633280512. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.50 while its Price-to-Book (P/B) ratio in mrq is 2.73. Its current Enterprise Value per Revenue stands at 6.781 whereas that against EBITDA is -6.378.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.17, which has changed by 0.5017836 over the last 52 weeks, in comparison to a change of 0.092761636 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $8.21. The 50-Day Moving Average of the stock is 6.31%, while the 200-Day Moving Average is calculated to be -3.63%.
Shares Statistics:
ZYME traded an average of 580.04K shares per day over the past three months and 451380 shares per day over the past ten days. A total of 69.58M shares are outstanding, with a floating share count of 67.74M. Insiders hold about 3.58% of the company’s shares, while institutions hold 101.93% stake in the company. Shares short for ZYME as of 1748563200 were 7193207 with a Short Ratio of 12.40, compared to 1745971200 on 6615244. Therefore, it implies a Short% of Shares Outstanding of 7193207 and a Short% of Float of 13.389999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
